The companies will combine clinical genetic testing services with data management technology to support precision medicine for rare diseases.
Researchers developed a custom genetic drug for a child with a progressive neurological disorder, the New York Times reports.
The company operates three subsidiaries including Helomics, which provides tumor-analysis services for treatment personalization and new drug development.
The Seattle-based firm will use the funding to improve AI integration and further develop its Paris 3D tumor organoid diagnostic and drug discovery platform.
Tempus Labs researchers said they could match more than 40 percent of patients to a targeted treatment and 77 percent of patients to a relevant clinical trial.
The WGS analysis placed the triple-negative breast cancers into three groups, each of which had different treatment responses and prognoses.
The in vitro diagnostic uses next-generation sequencing to detect clinically actionable genetic variants to guide therapy selection for cancer patients.
The European companies aim to link individuals who have used direct-to-consumer genetic tests with clinical trials and other research programs.
A European study, published today in NEJM, used a POC, PCR-based system to perform CYP2C19 genotyping to guide platelet inhibitor therapy.
The German company's new Genome Enhancer product is an adaptation of its flagship multi-omics software for clinicians and biologists without bioinformatics expertise.
The US Department of Justice has proposed a rule change to enable DNA to be collected from migrants, the Associated Press reports.
Bernard Fisher, a surgeon who changed how breast cancer is treated, has died at 101, the New York Times reports.
A Washington Post columnist writes that she is skeptical about DNA-based diets.
In PNAS this week: recurrent inactivation of DEPDC5 in gastrointestinal stromal tumors, taxonomic reliability of GenBank sequences, and more.